Natalizumab therapy of multiple sclerosis

Area of Science:

• Neuroimmunology
• Neurology
• Demyelinating diseases

Background:

• Multiple sclerosis (MS) is a leading cause of neurological disability in young adults.
• It affects approximately 1 million people globally.
• MS is characterized by autoimmune-mediated inflammation targeting the central nervous system.

Purpose of the Study:

• To elucidate the underlying mechanisms of multiple sclerosis pathogenesis.
• To describe the clinical course and progression of MS.
• To highlight the role of inflammation and demyelination in MS-related disability.

Main Methods:

• Review of current understanding of MS pathophysiology.
• Description of disease course based on clinical presentation and imaging.
• Analysis of inflammatory processes in the central nervous system.

Main Results:

• MS typically begins with a relapsing-remitting course (85-90%) or primary progressive onset (10-15%).
• Inflammatory T-cell attacks damage myelin and oligodendrocytes, leading to demyelination and axonal injury.
• Asymptomatic lesions are common, and persistent inflammation causes cumulative damage and eventual secondary progressive MS.

Conclusions:

• MS is an autoimmune inflammatory disease causing demyelination and axonal damage.
• Accumulated damage leads to progressive disability and the secondary progressive phase of MS.
• Understanding these mechanisms is crucial for managing MS and mitigating disability.